Jeff Douglas, PharmD, is Head of Clinical Operations at MyoKardia, a growing cardiovascular biopharma company in the Bay Area. Jeff is a drug development leader with >25 years' of global clinical research experience, diversified across clinical settings, including large and small biopharma, contract research organization (CRO), pharmacy and health care institutions. Prior to this engagement, Jeff hosted two sessions earlier this year with a diverse set of >60 Clinical Operations Leaders across small, medium and large biopharma and biotech ranging from <10 to 100K employees, virtually for in-the-moment conversations about COVID-19 in the clinical development ecosystem.

He is eager to answer questions as well as share ideas and expertise managing the impact of the COVID-19 pandemic on patient safety and clinical trial continuity, in particular: Ensuring patient safety, enrollment management, patient telemonitoring, potential restrictions for travel and/or scheduling of clinical visits Data collection strategies through remote SDV, risk-based data handling, data prioritization and analyses planning Health authorities’ guidance, potential impact to inspections or filings Benefit risk assessments for resuming studies and planning for resurgence.